2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

ASCO 2013 - Poster: CA184-095: A randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer

CHICAGO, IL USA (UroToday.com) - Presented by Tomasz M Beer,1 Christopher Logothetis,2 Padmanee Sharma,2 Yohann Loriot,3 Karim Fizazi,3 Alberto Bossi,4 Eugene D Kwon,5 M Brent McHenry,6 Paul Gagnier,6 Winald Gerritsen7 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 Beer Ipilimumab poster thumb

1 Oregon Health & Science University Knight Cancer Institute, Portland, OR; 2The University of Texas M. D. Anderson Cancer Center, Houston TX; 3Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 4Institut Gustave Roussy, Villejuif, France; 5Mayo Clinic, Rochester, MN; 6Bristol-Myers Squibb Company, Wallingford, CT; 7Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

 

asco x

View Full ASCO 2013 Coverage